Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC for Dopamine Oxidation in Parkinson's Disease
NCT03104725Phase 1Terminated
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Sep 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of acetylcysteine in Parkinson's disease (PD) (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Mean Percent Change in Cerebrospinal Fluid Concentration of 5-S-cysteinyl-dopamine at Day 3. Started Sep 2017; status: terminated.
02
Drugs
acetylcysteine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03104725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104725.